<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Bioventus CEO cites SmartTRAK HA Market Stats in Durolane Approval

Posted by Rebecca Gonzalez on 9/10/17 9:00 AM

Durham-based Bioventus has received approval from the U.S. Food and Drug Administration for its treatment, Durolane.

The single-injection product treats knee osteoarthritis pain. The company plans to launch Durolane in the U.S. early next year.

Citing BioMedGPS SmartTRAK, Bioventus CEO Tony Bihl said in an email that “the 2016 entire HA market in the US (1-shot, 2-shot, 3-shot and 5-shot) was about $979 million.”

Read More

Topics: Orthopedic

Historical Controls Remove Barrier in Cartilage IDE Studies

Posted by Sharon O'Reilly on 5/3/17 1:52 PM

FDA allowing use of historical controls may overcome a significant barrier and expedite pt enrollment in cartilage repair IDE trials notes Jack Farr, MD, at 2016 ICRS.

Read More

Topics: Orthopedic

Greater Need for Cartilage Repair in Ankle vs Knee

Posted by Sharon O'Reilly on 4/28/17 8:15 PM

Ironically, there is a greater need for a cartilage replacement technology in the ankle than in the knee, reports Richard Ferkel, MD, in a video interview with BioMedGPS at 2016 ICRS. The frequency of OCD lesions of the talar dome is about 5X greater than in the knee based on Ferkel's experience, who emphasizes the need for a single stage cartilage repair technology.

Read More

Topics: Orthopedic

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts